![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
May 20, 2026
This phase 3 clinical trial is comparing aromatase inhibitors and ribociclib, with and without chemotherapy, to prevent recurrence
April 24, 2026
This phase 2 trial is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
April 24, 2026
The latest clinical trial findings in breast cancer, cancer control and survivorship, health equity, leukemia, melanoma, and NCI-MATCH
April 24, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
March 30, 2026
The co-chairs reflect on the rapidly evolving definition of sensitive research data and highlight priorities for building secure data environments that sustain patient protection and public trust
March 30, 2026
This phase 3 clinical trial is evaluating a less intensive treatment approach for adults aged 75+ with early-stage melanoma
April 24, 2026
This phase 3 trial seeks to determine if there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
March 30, 2026
These studies aim to improve patient outcomes and well-being by examining complex interactions between patients, providers, and care delivery systems
March 30, 2026
The latest findings in breast cancer, cancer care delivery research, head and neck cancer, leukemia, and radiation therapy
March 30, 2026
Timely information about research presented at medical meetings, recognition of research leaders, and more
February 27, 2026
Progress in geriatric oncology, reflections on regulatory complexity, and an exciting new trial in small cell lung cancer
February 27, 2026
This phase 2 trial is evaluating whether broccoli sprout extract (sulforaphane) will reduce the risk of melanoma returning